FOXA1 and prostate adenocarcinoma: Ultimately, therapeutic targeting of FOXA1 and/or proteins that collaborate with or covalently modify this TF33 presents an attractive strategy as FOXA1 is a common vulnerability in both PRAD and NEPC.